| Prev Close | 103.40 |
| Open | 102.65 |
| Day Low/High | 102.65 / 108.75 |
| 52 Wk Low/High | 28.35 / 109.85 |
| Volume | 456.74K |
| Avg Volume | 909.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 37.21M |
| Market Cap | 3.90B |
| EPS | -8.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress,...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that on August 15, 2017 the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit...
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2017.
Jim Cramer is bullish on Philip Morris, 3M and Becton Dickinson; but he's bearish on Blue Apron and Puma Biotechnology.
Jim Cramer says history doesn't have to repeat itself. You don't want to miss another opportunity in the highly visible FANG-style stocks.
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has issued its Day-180 List of Outstanding...
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that NERLYNX™ (neratinib) tablets, formerly known as PB272, is now commercially available by prescription in the United States.
Former Attorney General of Louisiana, Charles C. Foti, Jr.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.
Puma Biotechnology, Inc. (Nasdaq: PBYI) today announced that the U.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that targeted patient enrollment in the Phase III NALA trial of the Company's lead drug candidate PB272 (neratinib) in patients with...
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc.
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Puma Biotechnology, Inc.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.
It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.
This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast Cancer Research Consortium TBCRC 022) of...
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.
